Literature DB >> 31143522

Neo-antigen specific memory T-cell responses in healthy individuals.

Morten Orebo Holmström1,2, Hans Carl Hasselbalch1, Mads Hald Andersen2,3.   

Abstract

The driver mutations in exon 9 of the calreticulin protein have only been identified in patients with myeloid cancers. We recently demonstrated that healthy individuals display strong and frequent T-cell responses towards this mutation. This memory T-cell response is likely evidence of the elimination of mutated cells in healthy individuals.

Entities:  

Keywords:  Neoantigens; calreticulin; cancer immunoediting; hematological cancer; memory T-cells

Year:  2019        PMID： 31143522      PMCID： PMC6527287          DOI： 10.1080/2162402X.2019.1599640

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Myeloproliferative Neoplasms.

Authors:  Jerry L Spivak
Journal:  N Engl J Med       Date:  2017-06-01       Impact factor: 91.245

Review 2.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

3.  The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms.

Authors:  M O Holmström; C H Riley; I M Svane; H C Hasselbalch; M H Andersen
Journal:  Leukemia       Date:  2016-08-18       Impact factor: 11.528

4.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

5.  A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.

Authors:  Ulrich Keilholz; Anne Letsch; Antonia Busse; Anne Marie Asemissen; Sandra Bauer; Igor Wolfgang Blau; Wolf-Karsten Hofmann; Lutz Uharek; Eckhard Thiel; Carmen Scheibenbogen
Journal:  Blood       Date:  2009-04-23       Impact factor: 22.113

6.  The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.

Authors:  M O Holmström; E Martinenaite; S M Ahmad; Ö Met; C Friese; L Kjær; C H Riley; P Thor Straten; I M Svane; H C Hasselbalch; M H Andersen
Journal:  Leukemia       Date:  2017-07-05       Impact factor: 11.528

Review 7.  The three Es of cancer immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

8.  Effect of mutation order on myeloproliferative neoplasms.

Authors:  Christina A Ortmann; David G Kent; Jyoti Nangalia; Yvonne Silber; David C Wedge; Jacob Grinfeld; E Joanna Baxter; Charles E Massie; Elli Papaemmanuil; Suraj Menon; Anna L Godfrey; Danai Dimitropoulou; Paola Guglielmelli; Beatriz Bellosillo; Carles Besses; Konstanze Döhner; Claire N Harrison; George S Vassiliou; Alessandro Vannucchi; Peter J Campbell; Anthony R Green
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

9.  High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals.

Authors:  M J Pittet; D Valmori; P R Dunbar; D E Speiser; D Liénard; F Lejeune; K Fleischhauer; V Cerundolo; J C Cerottini; P Romero
Journal:  J Exp Med       Date:  1999-09-06       Impact factor: 14.307

10.  High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals.

Authors:  Morten O Holmström; Shamaila M Ahmad; Uffe Klausen; Simone K Bendtsen; Evelina Martinenaite; Caroline H Riley; Inge M Svane; Lasse Kjær; Vibe Skov; Christina Ellervik; Niels Pallisgaard; Hans C Hasselbalch; Mads H Andersen
Journal:  Blood Cancer J       Date:  2019-01-17       Impact factor: 11.037
  10 in total
  1 in total

1.  Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer.

Authors:  Tao Dao; Martin G Klatt; Tatyana Korontsvit; Sung Soo Mun; Sean Guzman; Marissa Mattar; Oliver Zivanovic; Chrisann K Kyi; Nicholas D Socci; Roisin E O'Cearbhaill; David A Scheinberg
Journal:  Cancer Immunol Immunother       Date:  2020-10-29       Impact factor: 6.968
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.